MEI Pharma, Inc. MEIP Balance Sheet

Mei pharma, inc. (MEIP)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11
ASSETS
Current assets:
Cash and cash equivalents
7,438	8,638	5,984	9,590	7,426	8,748	6,118	13,309	6,198	7,339	6,958	8,458	11,644	15,050	13,789	10,837	14,291	13,674	17,876	18,722	20,465	23,657	17,041	13,777	19,670	39,762	31,504	35,573	24,167	26,877	3,713	6,202	2,722	4,991	4,800	3,858
Short-term investments
85,360	95,243	59,932	64,899	74,864	84,667	84,646	89,434	30,004	35,102	40,065	45,107	45,116	40,104	45,112	35,081	35,111	40,116	40,142	45,057	50,055	55,051	25,021	35,016	35,007	20,001	-	-	-	-	-	-	-	-	-	-
Total cash, cash equivalents and short-term investments
92,798	103,881	65,916	74,489	82,290	93,415	90,764	102,743	36,202	42,441	47,023	53,565	56,760	55,154	58,901	45,918	49,402	53,790	58,018	63,779	70,520	78,708	42,062	48,793	54,677	59,763	-	-	-	-	-	-	-	-	-	-
Common stock proceeds receivable (Note 10)
-	-	-	5,274	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
2,604	2,564	2,135	2,435	3,153	2,418	3,671	1,586	854	772	641	1,758	2,756	2,668	1,741	831	1,102	787	596	502	592	533	353	497	861	893	602	456	260	197	123	146	543	200	108	272
Total current assets
95,402	106,445	68,051	82,198	85,443	95,833	94,435	104,329	37,056	43,213	47,664	55,323	59,516	57,822	60,642	46,749	50,504	54,577	58,614	64,281	71,112	79,241	42,415	49,290	55,538	60,656	32,106	36,029	24,427	27,074	3,836	6,348	3,265	5,191	4,908	4,130
Intangible assets, net
235	244	253	261	270	279	287	296	305	314	322	331	340	348	357	366	374	383	392	401	409	418	427	435	444	453	461	470	479	488	496	-	-	-	-	-
Property and equipment, net
986	416	619	204	213	193	28	32	36	40	45	50	35	40	46	49	53	56	62	68	77	79	75	83	61	46	50	48	41	22	23	25	28	31	35	38
Total assets
96,623	107,105	68,923	82,663	85,926	96,305	94,750	104,657	37,397	43,567	48,031	55,704	59,891	58,210	61,045	47,164	50,931	55,016	59,068	64,750	71,598	79,738	42,917	49,808	56,043	61,155	32,617	36,547	24,947	27,584	4,355	6,373	3,293	5,222	4,943	4,168
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
2,492	3,038	3,098	4,787	1,969	2,158	1,555	3,643	1,259	1,089	751	585	242	382	749	1,079	466	448	253	863	2,711	2,152	1,111	1,708	700	809	557	537	528	448	533	594	441	381	331	328
Accrued liabilities
5,287	3,835	3,295	4,559	5,685	4,766	2,489	3,454	2,382	3,230	2,767	3,285	3,711	2,938	2,428	4,433	3,559	2,930	2,874	4,096	3,927	4,730	4,197	2,908	2,818	1,619	908	1,138	1,254	1,349	1,097	1,180	1,058	915	834	921
Deferred revenue
2,478	3,056	3,675	4,955	4,197	3,980	740	788	843	890	947	996	1,036	-	14,043	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	423	1,125
Total current liabilities
10,257	9,929	10,068	14,301	11,851	10,904	4,784	7,885	4,484	5,209	4,465	4,866	4,989	3,320	17,220	5,512	4,025	3,378	3,127	4,959	6,638	6,882	5,308	4,616	3,518	2,428	1,465	1,675	1,782	1,797	1,630	1,774	1,499	1,296	1,588	2,374
Deferred revenue, long-term
2,817	3,108	3,231	2,819	4,222	5,161	-	-	-	-	-	-	-	-	1,494	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability
9,051	16,783	8,344	17,613	31,971	26,770	50,207	46,313	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
22,125	29,820	21,643	34,733	48,044	42,835	54,991	54,198	-	-	-	4,866	-	-	18,714	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and contingencies (Note 7)
-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders' equity:
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding
-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-
Common stock, $0.00000002 par value; 226,000 shares authorized; 105,999 and 73,545 shares issued and outstanding at March 31, 2020 and June 30, 2019, respectively
-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in-capital
333,256	331,714	281,492	279,148	272,153	270,387	268,700	264,858	228,059	227,556	226,685	225,169	224,890	224,276	223,602	218,653	218,137	217,498	216,700	215,930	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in-capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	215,437	214,403	170,047	168,637	167,429	166,244	132,345	131,169	116,247	116,116	90,300	89,710	84,804	84,667	82,555	79,382
Accumulated deficit
-258,758	-254,429	-234,212	-231,218	-234,271	-216,917	-228,941	-214,399	-195,146	-189,198	-183,119	-174,331	-169,988	-169,386	-181,271	-177,001	-171,231	-165,860	-160,759	-156,139	-150,477	-141,547	-132,438	-123,445	-114,904	-107,517	-101,193	-96,297	-93,082	-90,329	-87,575	-85,111	-83,010	-80,741	-79,200	-77,588
Total stockholders' equity
74,498	77,285	47,280	47,930	37,882	53,470	39,759	50,459	32,913	38,358	43,566	50,838	54,902	54,890	42,331	41,652	46,906	51,638	55,941	59,791	64,960	72,856	37,609	45,192	52,525	58,727	31,152	34,872	23,165	25,787	2,725	4,599	1,794	3,926	3,355	1,794
Total liabilities and stockholders' equity
96,623	107,105	68,923	82,663	85,926	96,305	94,750	104,657	37,397	43,567	48,031	55,704	59,891	58,210	61,045	47,164	50,931	55,016	59,068	64,750	71,598	79,738	42,917	49,808	56,043	61,155	32,617	36,547	24,947	27,584	4,355	6,373	3,293	5,222	4,943	4,168